April 11 is World Parkinson’s Day. With over 10 million people affected worldwide and no cure yet, Investigator-Initiated Trials (IITs) offer the flexibility to test novel targets and mechanisms, pav...
In the life-critical exploration of anticancer drug development, the success or failure of clinical trials largely depends on the scientific rigor and foresight of their statistical strategies. As a g...
A conversation with Ms. Ying Xiaowei, EVP of GCP ClinPlus, on how US biotech companies can utilize China as a strategic accelerator for their global development plans.Q: What is the strategic value fo...
— Insights from China’s rapidly evolving next-generation cell therapy fieldIn Vivo CAR-T—directly delivering CAR genes into the human body to engineer immune cells in situ—is emerging as one of th...
GCP ClinPlus is honored to have been the CRO partner for OcuMension’s anti-VEGF drug OT-702, delivering comprehensive data management, statistical programming, and biostatistics support throughout it...
We are pleased to announce that the long-acting GLP-1 therapy Visepegenatide Injection has received marketing approval from the NMPA on November 14, 2025! As the clinical research partner of PegBio, G...
